Tokyo Stock Exchange

Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market

Retrieved on: 
Wednesday, March 8, 2023
Drug discovery, TSE, Tokyo Stock Exchange, Nordic Growth Market, GPCR, Pharmaceutical industry

Tokyo, Japan and Cambridge, UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, is pleased to announce it has received approval from the Tokyo Stock Exchange, Inc. (“TSE”) to change the market on which the Company's shares are listed from the Growth Market segment to the Prime Market segment, effective March 15, 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, is pleased to announce it has received approval from the Tokyo Stock Exchange, Inc. (“TSE”) to change the market on which the Company's shares are listed from the Growth Market segment to the Prime Market segment, effective March 15, 2023.
  • We are deeply grateful to our shareholders and stakeholders for their continued support over many years.
  • Sosei Heptares is engaged in drug discovery and development that requires a long term investment horizon, and therefore this long term support has been crucial in allowing us to create a solid company, able to move to the Prime Market.
  • For further details regarding the change of our market segment listing to the TSE Prime Market, please see the Japan Exchange Group’s website ( https://www.jpx.co.jp/english/ ).

Nexon Announces the March 30 Release Date for Wars of Prasia

Retrieved on: 
Thursday, March 2, 2023
Internet, Electronic Games, Technology, Entertainment, Software, NEXON, Android, IOS, Tokyo Stock Exchange, Weapon, Crazyracing Kartrider, Map, Freedom, Nexon, MapleStory, Dungeon & Fighter, Nikkei, Acquisition, MMORPG, Massively multiplayer online role-playing game, Video game, Virtual world, Prasiae

NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the upcoming release of Wars of Prasia.

Key Points: 
  • NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the upcoming release of Wars of Prasia.
  • Wars of Prasia is a game that can be enjoyed anytime, anywhere, with rich graphics and deeply immersive gameplay on both PC and mobile platforms.
  • For details and the latest trailers, please visit Wars of Prasia official website, and YouTube channel (Korean-language only).
  • In 2021, Nexon completed the acquisition of Embark Studios AB, a company based in Stockholm, Sweden, developing multiple projects for global release.

Nexon’s MapleStory: The Legends of Maple Coming to China

Retrieved on: 
Monday, February 27, 2023
Entertainment, Apps, Applications, Technology, Online, Software, Electronic Games, Tokyo Stock Exchange, Dungeon & Fighter, Tencent, NEXON, Tencent Games, Crazyracing Kartrider, Slime, Acquisition, MapleStory, Legend, Nexon, Nikkei, Video game, Virtual world, Maple

NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced MapleStory: The Legends of Maple, a special localized release of the breakaway mobile hit MapleStory M, is in development for release in China.

Key Points: 
  • NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced MapleStory: The Legends of Maple, a special localized release of the breakaway mobile hit MapleStory M, is in development for release in China.
  • Based on Nexon’s blockbuster MapleStory franchise, MapleStory: The Legends of Maple integrates classic elements of the franchise with a new game experience featuring classic characters including Blue Snail, Slime and Orange Mushroom.
  • Nexon has carefully optimized and polished an outstanding mobile experience that will be both familiar and fresh to players.
  • More information on the release schedule of MapleStory: The Legends of Maple will be announced at a later date.

Embark Studios’ THE FINALS Begins a Global Closed-Beta Test March 7

Retrieved on: 
Thursday, February 23, 2023
Entertainment, Apps, Applications, Technology, Online, Electronic Games, Internet, Tokyo Stock Exchange, ARC, Dungeon Fighter Online, Riviera, NEXON, Steam, Crazyracing Kartrider, Acquisition, MapleStory, Weapon, Nexon, Movement, Nikkei, Video game, Virtual world

NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the March 7 start of a global closed-beta test for THE FINALS, the first game from the company’s Embark Studios.

Key Points: 
  • NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the March 7 start of a global closed-beta test for THE FINALS, the first game from the company’s Embark Studios.
  • In 2021, Embark was acquired in full by NEXON Co., Ltd. Embark has two games in production, THE FINALS and ARC Raiders.
  • In 2021, Nexon completed the acquisition of Embark Studios AB, a company based in Stockholm, Sweden, developing multiple projects for global release.
  • THE FINALS, ARC RAIDERS and EMBARK trademarks and logos are trademarks or registered trademarks of Embark Studios AB.

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

Retrieved on: 
Monday, February 20, 2023
Society, Dana–Farber Cancer Institute, Circulatory system, Perk, Tokyo Stock Exchange, Temozolomide, Mothers (Tokyo Stock Exchange), Tissue, Brain mapping, Integrin alpha M, HIV disease progression rates, Immunohistochemistry, Harvard Medical School, Glioblastoma, Society for Brain Mapping and Therapeutics, Professor, Therapy, Biopsy, Cleveland Clinic, CD74, Congress, Molecular medicine, TMZ, Part, CD3, Neoplasm, Code, Principal, Doctor of Philosophy, Medicine, Medical imaging, Neurology

MN-166-GBM-1201; NCT03782415) at the 20th Annual World Congress of SBMT (Society for Brain Mapping and Therapeutics) held on February 16 - 19, 2023, in Los Angeles, CA.

Key Points: 
  • MN-166-GBM-1201; NCT03782415) at the 20th Annual World Congress of SBMT (Society for Brain Mapping and Therapeutics) held on February 16 - 19, 2023, in Los Angeles, CA.
  • This tumor analysis study was a collaborative effort between MediciNova, Dr. Patrick Wen (Dana- Farber Cancer Institute), and Dr. Lathia (Cleveland Clinic Foundation).
  • Immunohistochemistry was performed on resected tumor tissue to evaluate MIF (macrophage migration inhibitory factor), pERK, Ki67, CD3, CD11b, and CD74.
  • Recently, we have completed study enrollment with MN-166-GBM-1201 study and look forward to the upcoming data analysis with more tissue samples.”

Nidec Completes the Acquisition of the Shares of Italian Machine Tool Manufacturer PAMA and Its Affiliates

Retrieved on: 
Wednesday, February 1, 2023
Other Manufacturing, Technology, Engineering, Other Technology, Manufacturing, Machinery, Machine Tools, Metalworking & Metallurgy, Hardware, Robotics, PAMA, Tokyo Stock Exchange, Disclosure, Sale, Growth, Video game

In addition, PAMA enjoys stable annual sales in Europe, North America, and China – the country where PAMA has been in business since 1988.

Key Points: 
  • In addition, PAMA enjoys stable annual sales in Europe, North America, and China – the country where PAMA has been in business since 1988.
  • Nidec Machine Tool Corporation and Nidec OKK Corporation, two Nidec Group companies whose main products are gear cutting machines, large machine tools and machining centers, have been in need of further developing the multitasking and 5-axis machining technology as well as expanding its lineup of boring and milling machines in the large machine tools space.
  • The annual sales of Nidec Machine Tool, Nidec OKK, and PAMA combined are approximately 87 billion yen.
  • This press release contains forward-looking statements regarding the intent, belief, strategy, plans or expectations of the Nidec Group or other parties.

Reliance Standard Life Insurance and Matrix Absence Management Rebrand as Reliance Matrix, Delivering High-Tech and High-Touch Solutions to the U.S. Employee Benefits and Absence Management Markets

Retrieved on: 
Monday, January 23, 2023
Legal, Technology, Insurance, Human Resources, Consulting, Other Technology, Professional Services, Data Management, Other Professional Services, Tokyo Stock Exchange, Retirement, Consultant, Workforce, Silicon, Risk, Index, Tokio Marine, TPA, Tokio Marine Nichido, Multimedia, Society, Health insurance, Sales, Financial services, Matrix

The two industry leaders have joined forces to bring integrated and personalized employee benefits, absence management and workforce productivity solutions to the U.S. employer market.

Key Points: 
  • The two industry leaders have joined forces to bring integrated and personalized employee benefits, absence management and workforce productivity solutions to the U.S. employer market.
  • View the full release here: https://www.businesswire.com/news/home/20230123005009/en/
    “Human capital is an employer’s most precious asset,” said Chris Fazzini, President and CEO of Reliance Matrix.
  • Reliance Matrix markets solutions through independent brokers, agents, consultants and technology partners nationwide.
  • Born in 1907, Reliance Standard Life Insurance Company is a leading provider of employee benefits, absence management and retirement savings solutions.

Appier records its first profitable year and forecasts profitable growth for 2023

Retrieved on: 
Monday, February 13, 2023
Automation, Tokyo Stock Exchange, FX, Acceleration, Investment, Digital content, Yoy, TAM, Acquisition, EBITDA, Entrepreneurship, Martech, Customer, Synthetic media, Mother, Generative, CAC, Marketing, BFSI, Growth, Post Consumer Brands, TSE, LTV, Digital recording, Customer acquisition cost, Retail, Film industry, Video game, Sales, Kevin Appier, E-commerce, AI

TAIPEI, Feb. 13, 2023 /PRNewswire/ -- 

Key Points: 
  • This year marks growth acceleration for Appier for four years in a row, as annual gross profit more than tripled in the last four years to accelerate to 60% YoY.
  • Northeast Asia (63%) continued to reach high growth despite a large revenue base, while revenues in Greater China (20%) were mainly driven by vertical growth.
  • Appier's 2023 guidance comes with forecasted annual revenue growth of 31% (34% on FX neutral basis) to reach 25.5 billion yen.
  • The exponential growth of Generative AI and its potential has widened the space for MarTech applications.

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

Retrieved on: 
Wednesday, February 8, 2023
Safety, Tokyo Stock Exchange, COVID-19, Health Canada, Quality of life, University Health Network, Mothers (Tokyo Stock Exchange), Long, Code, Patient, Clinical trial, Pharmaceutical industry, Long COVID

The trial, entitled REcovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine, or “RECLAIM,” is a collaboration between MediciNova and the University Health Network, the largest hospital-based research program in Canada.

Key Points: 
  • The trial, entitled REcovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine, or “RECLAIM,” is a collaboration between MediciNova and the University Health Network, the largest hospital-based research program in Canada.
  • MediciNova will supply the study drug and will provide regulatory and safety follow-up support.
  • D, M.P.H., Chief Medical Officer, MediciNova, Inc., commented, “Since COVID-19 became a global health threat, multiple vaccines and treatment options became available, yet not many treatment options have been evaluated in COVID-19 sequelae, so-called Long COVID.
  • We are very excited about the initiation of this multi-arm Phase 2/3 trial to evaluate MN-166 as a drug candidate for Long COVID.”

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

Retrieved on: 
Monday, January 30, 2023
Psychiatry, UCLA, AUD, MD, Tokyo Stock Exchange, National Institute on Alcohol Abuse and Alcoholism, Principal, Mothers (Tokyo Stock Exchange), NIH, MPH, Code, NIAAA, Clinical trial, ABPP, University, Pharmaceutical industry, Psychology, Doctor of Philosophy

This clinical trial was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Key Points: 
  • This clinical trial was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
  • The clinical trial evaluated MN-166 (ibudilast) as a potential treatment to decrease alcohol consumption in treatment-seeking individuals diagnosed with AUD.
  • MediciNova provided drug supply and regulatory support for the clinical trial.
  • Lara Ray, PhD, Principal Investigator of the study, commented, “We have completed enrollment and are conducting follow-up on the last of the participants.